CSIMarket
 
Nyxoah Sa  (NASDAQ: NYXH)
 

Nyxoah Sa's Customers Performance

NYXH



 
NYXH's Source of Revenues During the corresponding time, Nyxoah Sa recorded a revenue increase by 156.29 % year on year, While revenue at the Nyxoah Sa's corporate clients

• List of NYXH Customers




for the same period Nyxoah Sa recorded revenue increase by 156.29 % year on year,

• List of NYXH Customers

Nyxoah Sa's Business Units
Germany    40.49 % of total Revenue
Spain    0.13 % of total Revenue
Switzerland    2.82 % of total Revenue
Austria    0.15 % of total Revenue
Netherlands    1.18 % of total Revenue
UAE    5.08 % of total Revenue
Italy    0.25 % of total Revenue
England    7.36 % of total Revenue
US    32.93 % of total Revenue






Nyxoah Sa's Comment on Sales, Marketing and Customers



The company serves approximately 125 of the top 400 HGNS accounts in the United States through sales representatives or territory managers. It plans to expand coverage to all top 400 accounts by increasing its sales force to 85 representatives, with each representative supporting four to six customer accounts. The initial group of 25 sales representatives generated an average of $700,000 in annualized revenue in the U.S. during their first quarter of productivity. Revenue per representative is expected to increase to $1.0 million to $1.2 million annually by 2026 and exceed $2.0 million at full productivity. The company’s market includes patients with Obstructive Sleep Apnea (OSA), a sleep disorder affecting approximately 936 million people globally aged 30 to 69. Of these, about 425 million have moderate to severe OSA requiring treatment. There are over 5.3 million new moderate to severe OSA diagnoses annually, divided evenly between the United States (2.6 million) and initial target markets in Europe (2.6 million).





Nyxoah Sa’s Comment on Sales, Marketing and Customers


The company serves approximately 125 of the top 400 HGNS accounts in the United States through sales representatives or territory managers. It plans to expand coverage to all top 400 accounts by increasing its sales force to 85 representatives, with each representative supporting four to six customer accounts. The initial group of 25 sales representatives generated an average of $700,000 in annualized revenue in the U.S. during their first quarter of productivity. Revenue per representative is expected to increase to $1.0 million to $1.2 million annually by 2026 and exceed $2.0 million at full productivity. The company’s market includes patients with Obstructive Sleep Apnea (OSA), a sleep disorder affecting approximately 936 million people globally aged 30 to 69. Of these, about 425 million have moderate to severe OSA requiring treatment. There are over 5.3 million new moderate to severe OSA diagnoses annually, divided evenly between the United States (2.6 million) and initial target markets in Europe (2.6 million).








NYXH's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Nyxoah Sa 48.40 11.09 -100.90 20
SUBTOTAL 0.00 0.00 0.00 -

Sources: Nyxoah Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nyxoah Sa’s corporate clients.
For your research, we’ve provided 9 tables on Nyxoah Sa corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.